Patents Examined by Janet L. Andres
-
Patent number: 12036255Abstract: Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.Type: GrantFiled: January 9, 2023Date of Patent: July 16, 2024Assignees: Baylor College of Medicine, The United States Government as Represented by the Department of Veterans AffairsInventors: Anthony Maresso, Robert Ramig, Sabrina Green, Austen Terwilliger, Keiko Salazar, Justin R. Clark, Barbara Trautner
-
Patent number: 12016916Abstract: Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MFRS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.Type: GrantFiled: December 7, 2023Date of Patent: June 25, 2024Assignee: ImmunityBio, Inc.Inventor: Patrick Soon-Shiong
-
Patent number: 12005114Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.Type: GrantFiled: January 19, 2023Date of Patent: June 11, 2024Assignee: VAXTHERA SASInventor: Jorge E. Osorio
-
Patent number: 11993790Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.Type: GrantFiled: October 3, 2018Date of Patent: May 28, 2024Assignee: Prevail Therapeutics, Inc.Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
-
Patent number: 11986502Abstract: Compositions for affecting the intestinal microbiome of a mammalian subject can include a pharmaceutically-acceptable carrier and greater than or equal to 1×104 PFU/mL or PFU/mg of bacteriophage having a tropism that includes an obesogenic and/or inflammatory bacterium associated with an intestinal microbiome of a mammal. Processes for preparing the disclosed compositions can include isolating the bacteriophage from an environmental source, characterizing the bacteriophage, and combining the bacteriophage with the pharmaceutically acceptable carrier at greater than or equal to 1×104 PFU/mL or PFU/mg. Methods can include administering the disclosed compositions to a mammalian subject with or without co-administration of the disclosed probiotics.Type: GrantFiled: May 23, 2019Date of Patent: May 21, 2024Assignee: Optium, LLCInventors: Laura Bridgewater, Gongze Zhao
-
Patent number: 11919944Abstract: The disclosure relates generally to the field of immune binding proteins and method for obtaining immune binding proteins from genomic or other sources. The disclosure also relates to anti-SARS-CoV-2 antibodies that have been obtained from subjects who became immune to this coronavirus, and to methods of using these anti-SARS-CoV-2 antibodies. Methods for neutralizing SARS-CoV-2 are disclosed, as well treatments for SARS-COV-2 using the anti-SARS-CoV-2 antibodies.Type: GrantFiled: May 9, 2021Date of Patent: March 5, 2024Assignee: Augmenta Biosciences, Inc.Inventors: Christopher J. Emig, Rosanna Man Wah Chau, Payam Shahi, Kim-Xuan Nguyen, Yushuan Lai, Robin Emig, John Beaber, Steven Henry, Marco Antonio Mena
-
Patent number: 11911459Abstract: Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.Type: GrantFiled: November 30, 2022Date of Patent: February 27, 2024Assignee: Immunity Bio, Inc.Inventor: Patrick Soon-Shiong
-
Patent number: 11904013Abstract: An immunogenic composition, a SARS-CoV-2 vaccine and a vector are introduced. The immunogenic composition has a recombinant protein having a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and any polypeptide encoded by a polynucleotide which is at least 80% homologous with SEQ ID NO: 1-4, wherein the recombinant protein contains an IgG1 Fc protein fragment having a length of at least 6 amino acids; or a nucleic acid molecule encoding the recombinant protein. The SARS-CoV-2 vaccine has the above recombinant protein or the nucleic acid molecule encoding the above recombinant protein. The vector has the nucleic acid molecule encoding the above recombinant protein.Type: GrantFiled: May 3, 2021Date of Patent: February 20, 2024Assignee: ADIMMUNE CORPORATIONInventors: Chih-Hsiang Leng, Po-Hsu Su, Po-Kang Chen
-
Patent number: 11884926Abstract: In some aspects, the disclosure relates to compositions and methods for production of recombinant adeno-associated virus (rAAV) particles. The disclosure is based, in part, on isolated nucleic acids and systems that include only two vectors and are suitable for production of multiple different single gene viral vectors in a multiple small-scale campaign mode (e.g., 1013 to 1016 viral particles.Type: GrantFiled: February 1, 2019Date of Patent: January 30, 2024Assignee: University of MassachusettsInventors: Terence Flotte, Qiushi Tang, Allison Keeler-Klunk, Qin Su
-
Patent number: 11851478Abstract: The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.Type: GrantFiled: January 4, 2019Date of Patent: December 26, 2023Assignee: VANDERBILT UNIVERSITYInventor: James E Crowe, Jr.
-
Patent number: 11844818Abstract: The present invention relates to a Myoviridae bacteriophage Aer-HYP-3 (Accession number: KCTC 13479BP) isolated from nature, which has the ability to kill Aeromonas hydrophila bacteria and has the genome represented by SEQ ID NO: 1, and to a method of preventing and treating a disease caused by Aeromonas hydrophila bacteria using a composition containing the same as an active ingredient.Type: GrantFiled: February 18, 2019Date of Patent: December 19, 2023Assignee: Intron Blotechnology, Inc.Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Ji In Jung, Sang Hyeon Kang
-
Patent number: 11826391Abstract: An antibacterial formulation having a mixture of bacteriophages with lytic activity against strains of Salmonella spp. and a pharmaceutically and veterinarily acceptable vehicle, pH stabilizer and/or excipients. This formulation is for the prevention and treatment of infectious diseases caused by Salmonella spp. and different serovars; use and method for preventing or treating infectious diseases caused by Salmonella spp. in farm animals by administering the antibacterial formulation to a non-human animal orally.Type: GrantFiled: May 19, 2021Date of Patent: November 28, 2023Assignee: PHAGELAB CHILE SPAInventors: Nicolas Ferreira Soto, Mauro Canaval Alfaro, Pablo Cifuentes Palma, Daniel Tichy Navarro, Maria Sofia Zamudio Canas, Matias Aguilera Barrios, Trinidad Pizarro Black, Juan Sacre Ravera, Hans Pieringer Castro, Michael Pino Barrientos, Rodrigo Norambuena Venegas, Francisca Contreras Vera, Angelica Zavala Prati
-
Patent number: 11725192Abstract: The present disclosure provides methods for the separation and quantification of empty and full viral capsids (e.g., AAV capsids) within a viral preparation, such as a viral pharmaceutical composition or drug product.Type: GrantFiled: July 12, 2020Date of Patent: August 15, 2023Assignee: SANGAMO THERAPEUTICS, INC.Inventors: Santoshkumar Khatwani, Zhu Pirot
-
Patent number: 11504424Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.Type: GrantFiled: July 12, 2019Date of Patent: November 22, 2022Assignees: UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE LAVALInventors: Manuel Rosa-Calatrava, Guy Boivin, Julia Dubois, Mario Andres Pizzorno, Olivier Terrier, Marie-Eve Hamelin, Marie-Helene Cavanagh
-
Patent number: 10729762Abstract: This disclosure relates to recombinant bacteria, e.g. L. lactis, expressing heterologous pili containing human immunodeficiency virus (HIV) antigens. In certain embodiments, the recombinant bacteria are administered in combination with other HIV antigens, nucleic acids encoding HIV antigens, recombinant virus encoding HIV antigens, anti-viral agents and/or adjuvants in an effective amount to elicit a mucosal immune response against HIV.Type: GrantFiled: December 20, 2017Date of Patent: August 4, 2020Assignee: Emory UniversityInventors: Rama Rao Amara, June Scott, Bernard Quigley, Venkateswarlu Chamcha
-
Patent number: 10729754Abstract: Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.Type: GrantFiled: March 15, 2018Date of Patent: August 4, 2020Assignee: MIRROR BIOLOGICS, INC.Inventor: Michael Har-Noy
-
Patent number: 10725056Abstract: The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject. In other embodiments, the invention relates to methods for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV.Type: GrantFiled: December 22, 2016Date of Patent: July 28, 2020Assignees: BIOCRATES LIFE SCIENCES AG, IDCGS CLINICA DE DIAGNOSTICOS MEDICOS, CENTRO DE GENOMASInventors: Ismael Dale Cotrim Guerreiro Da Silva, Edson Guimaraes Loturco, Ricoardo Soubie Diaz, Therese Koal
-
Patent number: 10717778Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.Type: GrantFiled: September 29, 2015Date of Patent: July 21, 2020Assignees: DUKE UNIVERSITY, MACROGENICS, INC., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Barton F. Haynes, Guido Ferrari, Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Julia A. Sung, David M. Margolis, Liqin Liu, Jeffrey Lee Nordstrom
-
Patent number: 10690668Abstract: The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease.Type: GrantFiled: January 29, 2013Date of Patent: June 23, 2020Assignee: Temple University—Of The Commonwealth System Of Higher EducationInventors: Kamel Khalili, Ilker K. Sariyer
-
Patent number: 10676521Abstract: The present invention relates to methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs. Specifically, the disclosure provides methods and agents for preventing the establishment of HIV-1 latent reservoirs or for reducing the size of the reservoirs, the methods comprising administering to the subject a therapeutically effective amount of an isolated anti-HIV antibody, and administering to the subject two or more viral transcription inducers in effective amounts to induce transcription of an HIV provirus in the cells. Further provided are antibodies and viral transcription inducers used in the methods.Type: GrantFiled: July 21, 2015Date of Patent: June 9, 2020Assignee: The Rockefeller UniversityInventors: Michel Nussenzweig, Ariel Halper-Stromberg, Ching-Lan Lu